ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
456
views
0
references
Top references
cited by
223
Cite as...
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
16
shares
Share
Twitter
Sina Weibo
Facebook
Email
4,166
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
Trastuzumab--mechanism of action and use in clinical practice.
Author(s):
Clifford Hudis
Publication date:
2007-07-05
Journal:
The New England journal of medicine
Keywords:
Antibodies, Monoclonal
,
adverse effects
,
pharmacology
,
therapeutic use
,
Antibodies, Monoclonal, Humanized
,
Antineoplastic Agents
,
Breast Neoplasms
,
drug therapy
,
metabolism
,
Chemotherapy, Adjuvant
,
Humans
,
Receptor, Epidermal Growth Factor
,
Receptor, ErbB-2
,
analysis
,
drug effects
,
immunology
,
Signal Transduction
Read this article at
ScienceOpen
Publisher
PubMed
Cite as...
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Drug_transporters
Author and article information
Journal
PubMed ID::
17611206
DOI::
10.1056/NEJMra043186
ScienceOpen disciplines:
Chemistry
Keywords:
Antibodies, Monoclonal
,
adverse effects
,
pharmacology
,
therapeutic use
,
Antibodies, Monoclonal, Humanized
,
Antineoplastic Agents
,
Breast Neoplasms
,
drug therapy
,
metabolism
,
Chemotherapy, Adjuvant
,
Humans
,
Receptor, Epidermal Growth Factor
,
Receptor, ErbB-2
,
analysis
,
drug effects
,
immunology
,
Signal Transduction
Data availability:
ScienceOpen disciplines:
Chemistry
Keywords:
Antibodies, Monoclonal
,
adverse effects
,
pharmacology
,
therapeutic use
,
Antibodies, Monoclonal, Humanized
,
Antineoplastic Agents
,
Breast Neoplasms
,
drug therapy
,
metabolism
,
Chemotherapy, Adjuvant
,
Humans
,
Receptor, Epidermal Growth Factor
,
Receptor, ErbB-2
,
analysis
,
drug effects
,
immunology
,
Signal Transduction
Comments
Comment on this article
Sign in to comment
scite_
Similar content
4,166
β2-AR signaling controls trastuzumab resistance-dependent pathway.
Authors:
D. Liu
,
Z. Yang
,
T. Wang
…
Abstract P1-18-03: Pertuzumab (P) plus high-dose trastuzumab (H) for the treatment of central nervous system (CNS) progression after radiotherapy (RT) in patients (pts) with HER2-positive metastatic breast cancer (MBC): Primary efficacy analysis results from the phase II PATRICIA study
Authors:
Nancy U Lin
,
Priya Kumthekar
,
Solmaz Sahebjam
…
Gastric cancer and trastuzumab: first biologic therapy in gastric cancer.
Authors:
Krishna S Gunturu
,
Yanghee Woo
,
Nike T. Beaubier
…
See all similar
Cited by
648
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
Authors:
A Goldhirsch
,
W. C. Wood
,
A S Coates
…
Targeting cellular metabolism to improve cancer therapeutics
Authors:
Y. Zhao
,
E B Butler
,
Tricia Tan
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.
Authors:
Jeffrey Ross
,
Elzbieta Slodkowska
,
W Symmans
…
See all cited by
Version 1
Version 1
Version 1